High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer.
Twenty-two patients with metastatic breast cancer refractory to conventional chemotherapeutic agents were treated with 1-beta-D-arabinofuranosylcytosine (Ara-C) at a dose of 2 g/m2 over 2 h every 12 h for 3 doses at 21-day intervals. Two patients achieved partial remission, 3 patients had less than partial response.